Reuters logo
BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​
September 14, 2017 / 8:48 PM / 9 days ago

BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

Sept 15 (Reuters) - Flexion Therapeutics Inc

* Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

* Flexion Therapeutics Inc - ‍out-license agreement related to co’s FX005 sustained-release p38 MAP

* Flexion Therapeutics Inc - ‍pursuant to terms of out-license agreement, termination will be effective three months after company’s delivery of notice​

* Flexion Therapeutics Inc - ‍upon termination of out-license agreement, Flexion’s license rights pertaining to FX005 will revert to Astrazeneca​

* Flexion Therapeutics Inc - ‍upon termination of out-license agreement Flexion's milestone, royalty and patent maintenance obligations under agreement will cease​ Source text for Eikon: [bit.ly/2h5vOpA] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below